Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease

Zuoping Chen, Xiaojun Qian

Emergency Department, Yichun People's Hospital, Yichun 336000, China;

For correspondence:- Xiaojun Qian Email: weipymdrcw075@163.com

Accepted: 28 April 2022 Published: 31 May 2022

Citation: Chen Z, Qian X. Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease. Trop J Pharm Res 2022; 21(5):1037-1043 doi: 10.4314/tjpr.v21i5.18

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the clinical efficacy of montelukast/budesonide formoterol powder inhalation in treating chronic obstructive pulmonary disease (COPD) and its impact on serum high-sensitivity C-reactive protein (hs-CRP), cancer antigen 125 (CA-125), and interleukin (IL)-6 levels.

Methods: In total, 86 COPD patients treated in the clinic of Department of Respiratory Medicine in Yichun People’s Hospital between December 2019 and December 2020 were recruited and randomly assigned to group A and group B alternately at the point of admission. Group B received conventional treatment, while group A was treated with conventional treatment plus montelukast/budesonide formoterol powder inhalation.

Results: Patients receiving montelukast/budesonide formoterol powder inhalation showed lower scores for cough, sputum, and shortness of breath, compared conventional treatment (p < 0.001). Patients in group A showed lower serum levels of hs-CRP, CA-125, and IL-6 after treatment than those in group B (p < 0.05). Pulmonary function and arterial blood gas indices were significantly different between the two groups after treatment (p < 0.05). Montelukast/budesonide formoterol powder inhalation resulted in higher Generic Quality Of Life Inventory-74 (GQOLI-74) scores and 6-min walking distance (6MWD) scores in patients than conventional treatment (p < 0.001). Also, Group A had a lower incidence of adverse reactions than group B (p < 0.05).

Conclusion: Montelukast/budesonide formoterol powder inhalation has a better therapeutic effect versus conventional treatment, and improves patients' lung function and exercise tolerance. Further clinical trials are, however, required prior to general use in clinical practice.

Keywords: Montelukast, Budesonide formoterol powder inhaler, Chronic resistance lung, Clinical efficacy, High-sensitivity; C-reactive protein; Cancer antigen 12